Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 2/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20720787 | 0.91 | EGFR (0.44) | EGFRTOP2AEHMT2KDM1ARCOR1 | |
| SCHEMBL20734756 | 0.89 | EGFR (0.50) | EGFREHMT2KDM1ARCOR1KDM4E | |
| SCHEMBL19260524 | 0.84 | EGFR (0.50) | EGFRTOP2AHTR1BEHMT2KDM1A | |
| SCHEMBL11809733 | 0.83 | MAOA (0.60) | EHMT2PDPK1KDM4ETDP1 | |
| Trifluoroacetic Acid SCHEMBL19260723 | 0.81 | EGFR (0.46) | EGFRKDM4ECYP1A2CYP2D6 | |
| SCHEMBL19260666 | 0.80 | TLR7 (0.59) | EHMT2 | |
| SCHEMBL19260694 | 0.79 | SPIN1 (0.58) | EHMT2 | |
| SCHEMBL19272512 | 0.78 | EGFR (0.58) | EGFR | |
| Trifluoroacetic Acid SCHEMBL19260557 | 0.77 | EGFR (0.44) | EGFREHMT2KDM1ARCOR1KDM4E | |
| SCHEMBL20746183 | 0.76 | EHMT2 (0.57) | EGFREHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
| EP-3416963-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142947-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EGFR 4848/4885TOP2A 643/4885HTR1B 3083/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EGFR 4848/4885TOP2A 643/4885HTR1B 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.